Program
Please Note: All session times for the AACR Virtual Special Conference: Radiation Science and Medicine are U.S. Eastern Standard Time (EST).
Tuesday, March 2, 2021
- Welcome and Opening Keynote Lecture
- Plenary Session 1: Microenvironment
- Plenary Session 2: Exploiting the DNA Damage Response I
- Plenary Session 3: Exploiting the DNA Damage Response II
- Plenary Session 4: Immunotherapy
Wednesday, March 3, 2021
- Plenary Session 5: Hypoxia
- Plenary Session 6: Limiting Late Effects: Physics, Biology, and Genetics
- Plenary Session 7: Sirtuins, Cell Homeostasis, and Metabolism
- Plenary Session 8: Molecular Predictions
Tuesday, March 2, 2021
Welcome and Opening Keynote Lecture
10-10:40 a.m.
Keynote Lecture
Genomic architecture and targets in hypoxic tumors
Robert G. Bristow, University of Manchester, Manchester, United Kingdom
Break
10:40-10:55 a.m.
Plenary Session 1: Microenvironment
Session Chair: Conchita Vens, the Netherlands Cancer Institute, Amsterdam, Netherlands
10:55 a.m.-12:25 p.m.
Microenvironmental regulation of glioblastoma radioresistance
Philip J. Tofilon, National Cancer Institute, Bethesda, Maryland
Oxygen dependent resistance to PARP inhibitors
Amato Giaccia, University of Oxford, Oxford, United Kingdom
Angiotensin II receptor blockers modify the solid tumor microenvironment and improve radiation therapy response*
Kevin L. Bennewith, BC Cancer, Vancouver, BC, Canada
The impact of gut microbiota on radiotherapy-induced antitumor immune response
Andrea Facciabene, University of Pennsylvania, Philadelphia, Pennsylvania
Break
12:25-12:40 p.m.
Plenary Session 2: Exploiting the DNA Damage Response I
Session Chair: Amato Giaccia, University of Oxford, Oxford, United Kingdom
12:40-2:10 p.m.
Base excision repair and cancer
Joann B. Sweasy, University of Arizona Cancer Center, Tucson, Arizona
Enhancing the therapeutic ratio for glioblastoma by combining radiation therapy with PARP inhibitors
Anthony J. Chalmers, University of Glasgow, Glasgow, United Kingdom
SIRT2 promotes BRCA1-BARD1 heterodimerization through deacetylation*
David S. Yu, Emory University School of Medicine, Atlanta, Georgia
Exploiting DNA repair defects in head and neck squamous cell carcinoma
Conchita Vens, The Netherlands Cancer Institute, Amsterdam, Netherlands
Break
2:10-2:25 p.m.
Plenary Session 3: Exploiting the DNA Damage Response II
Session Chair: Charles G. Drake, Janssen Research and Development, Spring House, Pennsylvania
2:25-4:20 p.m.
Etiology of chromosomal rearrangements, and other DNA double-strand break repair outcomes
Jeremy Stark, City of Hope, Duarte, California
TGFβ regulation of DNA repair across cancer types predicts response to genotoxic therapies
Mary Helen Barcellos-Hoff, University of California San Francisco, San Francisco, California
Radiosensitization by targeting the NPM1/RAD51 axis*
Michael L. Freeman, Vanderbilt University School of Medicine, Nashville, Tennessee
Deciphering DNA end resection at DSBs
Dipanjan Chowdhury, Dana-Farber Cancer Institute, Boston, Massachusetts
Translation to clinical trials: Are we shooting the right arrows at the target?
Ricky Sharma, Varian Medical Systems, Palo Alto, California
not eligible for CME credit
Break
4:20-4:35 p.m.
Plenary Session 4: Immunotherapy
Session Chair: Ralph Weichselbaum, University of Chicago, Chicago, Illinois
4:35-6:05 p.m.
Differential immunological effects of carbon-ion versus photon radiation therapy
Charles G. Drake, Janssen Research and Development, Spring House, Pennsylvania
Integrating radiation therapy with immunotherapy
Marka R. Crittenden, Earle A. Chiles Research Institute, Portland, Oregon
Radiation modulates hepatic siphoning of T cells to improve immunotherapy efficacy*
Michael Green, University of Michigan, Ann Arbor, Michigan
Strategies to enhance the immunogenicity of radiation therapy
Silvia C. Formenti, Weill Cornell Medical College, New York, New York
Wednesday, March 3, 2021
Plenary Session 5: Hypoxia
Session Chair: Robert G. Bristow, University of Manchester, Manchester, United Kingdom
10-11:55 a.m.
Hypoxia-induced SETX links replication stress with the unfolded protein response
Ester M. Hammond, University of Oxford, Oxford, United Kingdom
Metabolic deregulation drives a redox vulnerability in pancreatic cancer
Marianne Koritzinsky, Princess Margaret Cancer Centre, Toronto, Ontario, Canada
Adenosine signaling and radiation-induced immunosuppressive changes to the tumor microenvironment*
Catherine S. Spina, Columbia University Irving Medical Center, New York, New York
Chromatin and gene transcription in hypoxia
Sonia Rocha, University of Liverpool, Liverpool, United Kingdom
Molecular landmarks of tumor hypoxia across cancer types
Paul Boutros, University of California Los Angeles, Los Angeles, California
Break
11:55 a.m.-12:10 p.m.
Plenary Session 6: Limiting Late Effects: Physics, Biology, and Genetics
Session Chair: David R. Gius, Mays Cancer Center UT Health San Antonio, San Antonio, Texas
12:10-1:40 p.m.
Preclinical studies with proton FLASH radiotherapy in mice and canines: Biological effects, biophysical considerations, and potential mechanisms
Constantinos Koumenis, University of Pennsylvania, Philadelphia, Pennsylvania
Optimizing stem cell nice for post-irradiation regeneration
Rob Coppes, University Medical Center Groningen, Groningen, Netherlands
Pulsed low-dose-rate radiation (PLDR) limits pancreatic pro-tumor stroma aggravation: Pre-clinical basis for an ongoing PLDR trail*
Janusz Franco-Barraza, Fox Chase Cancer Center, Philadelphia, Pennsylvania
Predicting radiotherapy outcomes: Radiogenomics and risk of radiotherapy toxicity
Catharine M.L. West, University of Manchester, Manchester, United Kingdom
Break
1:40-1:55 p.m.
Plenary Session 7: Sirtuins, Cell Homeostasis, and Metabolism
Session Chair: Ester M. Hammond, University of Oxford, Oxford, United Kingdom
1:55-3:50 p.m.
Lysine 68 acetylation directs MnSOD as a tetrameric detoxification complex versus a monomeric tumor promoter
David Gius, Mays Cancer Center UT Health San Antonio, San Antonio, Texas
The role of sirtuins in radiation-induced cardiac dysfunction
Carmen R. Bergom, Washington University in St. Louis, St. Louis, Missouri
Targeting FASN improves type I interferon responses in irradiated glioblastoma*
Mara De Martino, Weill Cornell Medicine, New York, New York
Sirt2: A tumor suppressor or promotor?
Fen Xia, University of Arkansas for Medical Sciences, Little Rock, Arkansas
Exploiting redox biology for selectively targeting cancer cells
Douglas R. Spitz, University of Iowa, Iowa City, Iowa
Break
3:50-4:05 p.m.
Plenary Session 8: Molecular Predictions
Session Chair: Mary Helen Barcellos-Hoff, University of California, San Francisco, San Francisco, California
4:05-5:35 p.m.
Gaps alone kill BRCA deficient cancer cells
Sharon Cantor, University of Massachusetts Medical School, Worcester, Massachusetts
Dysregulated metabolic and immune pathways underlying radiation fibrosis and lymphedema
Fei-Fei Liu, Princess Margaret Cancer Centre, Toronto, Ontario, Canada
Identification and characterization of the molecular mechanisms of SCLC chemo-radiation resistance*
Francesca Anna Carrieri, Johns Hopkins University, Baltimore, Maryland
Interaction of radiotherapy and immunotherapy: Maybe not what you think
Ralph Weichselbaum, University of Chicago Medicine, Chicago, Illinois
Closing Remarks
5:35-5:40 p.m.
David R. Gius, Mays Cancer Center UT Health San Antonio, San Antonio, Texas
*Short talk from proffered abstract